重组尿激酶原治疗对大鼠肺血栓栓塞症后血浆纤溶因子的影响

发布时间：2018-05-25 02:13

  本文选题：肺血栓栓塞症 + 重组尿激酶原　； 参考：《军事医学》2014年12期

【摘要】：目的观察重组尿激酶原(recombinant prourokinase,r Pro-UK)治疗大鼠肺血栓栓塞症(pulmonary tromboembolus,PTE)后血浆纤溶因子的变化及其意义。方法雄性SD大鼠28只,颈外静脉注入加热125-碘(125I)标记纤维蛋白原(Fib)自体血栓,复制大鼠PTE模型,随机分组如下:1正常对照组;2 PTE 5 d组,即在造模成功后观察5 d活杀;3 Pro-UK溶栓治疗组:分为多次给药亚组(PTE造模成功后第3天,予Pro-UK 1 mg/kg,后连续2 d给予Pro-UK 0.25 mg/kg,最后1 d给药2 h后与PTE 5 d组大鼠同时活杀)和单次给药亚组(PTE造模成功后第3天给予Pro-UK 1 mg/kg,后连续2 d给予生理盐水,活杀时间同PTE 5 d组大鼠)。每组7只,在实验结束时经颈动脉放血活杀动物,留取血浆标本测定尿激酶型纤溶酶原激活物(u-PA)、尿激酶型纤溶酶原激活物受体(u-PAR)、Fib的水平和α2-抗纤溶酶(α2-AP)的活性。结果 1多次给药亚组血浆u-PA、u-PAR水平较PTE 5 d组(Pu-PA0.05,Pu-PAR0.01)及单次给药亚组(Pu-PA0.01,Pu-PAR0.05)明显升高,与血栓溶解率正相关(ru-PA=0.766,P0.05;ru-PAR=0.785,P0.05)。2 r Pro-UK溶栓治疗后血浆Fib浓度和α2-AP活性与PTE 5 d组比较无显著差异(P0.05)。结论 1 r Pro-UK溶栓治疗可促进内皮细胞合成和分泌u-PA、u-PAR,有助于血栓溶解,这可能是r Pro-UK的一个重要的溶栓机制。2 r Pro-UK多次给药方案治疗大鼠PTE没有引起继发全身纤溶激活,具有纤维蛋白特异性。
[Abstract]:Objective to observe the changes and significance of plasma fibrinolytic factor in rats with pulmonary thromboembolism (PE) treated with recombinant urokinase propranase (Pro-UKR). Methods 28 male SD rats were injected into external jugular vein with 125-iodide 125I) to label fibrinogen (Fib) autothrombus, and the PTE model was established in rats. The rats were randomly divided into two groups as follows: 1 normal control group: 2 PTE 5 d group. The thrombolytic therapy group was divided into two groups: the treatment group was divided into three groups: the third day after the successful establishment of the model, the treatment group was divided into two groups: the third day after the successful establishment of the model, the treatment group was divided into three groups. The rats were given Pro-UK 1 mg / kg for 2 days, Pro-UK 0.25 mg / kg for 2 days, and the rats of PTE 5 d group for 2 h at the same time. The rats in the subgroup were given Pro-UK 1 mg / kg on the 3rd day after the model was successfully established, and then saline was given for 2 days. The killing time was the same as that of PTE group for 5 days. At the end of the experiment, 7 animals in each group were bled and killed through carotid artery. Plasma samples were collected to determine the levels of urokinase-type plasminogen activator (urokinase-type plasminogen activator), urokinase-type plasminogen activator receptor (urokinase type plasminogen activator receptor) and 伪 _ 2-antiplasminase (伪 _ 2-AP). Results (1) the plasma u-PA-PA-PA-PAR level in the multiple administration subgroup was significantly higher than that in the PTE 5-day group (Pu-PA0.05Pu-PAR0.01) and the single-dose subgroup (Pu-PA0.01Pu-PAR0.05). There was no significant difference in plasma Fib concentration and 伪 2-AP activity between the two groups after thrombolytic therapy, and there was no significant difference in plasma Fib concentration and 伪 2-AP activity between the two groups after thrombolytic therapy. Conclusion 1r Pro-UK thrombolytic therapy can promote endothelial cell synthesis and secretion of u-PA-PAu-PAR. this may be an important thrombolytic mechanism of r Pro-UK. 2 r Pro-UK regimen does not induce secondary systemic fibrinolytic activation in rats. It has the specificity of fibrin.
【作者单位】： 首都医科大学附属北京朝阳医院 呼吸与危重症医学科;北京呼吸疾病研究所;国家卫生和计划生育委员会(原卫生部)中日友好医院;郑州大学第一附属医院;
【分类号】：R563.5
，

本文编号：1931613